Dosage forms

The Worldwide Medical Oxygen Concentrators & Oxygen Cylinders Industry is Expected to Reach $4.62 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, General Health, Chemistry, Physical sciences, Oxygen, Medicine, Industrial gases, Respiratory therapy, Dosage forms, Medical equipment, Oxygen concentrator, Oxygen therapy, Gas cylinder, Oxygen firebreak

The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global medical oxygen concentrators & oxygen cylinders market size is expected to reach USD 4.62 billion by 2028 according to a new study.
  • Medical concentrators and cylinders are medical oxygen systems that are used to treat respiratory ailments and are commonly preferred by older patients who have limited mobility and rely on a consistent market supply.
  • The increasing market demand for medical concentrators and cylinders has resulted in the introduction and approval of new products in the market.

Canadian Vaping Association: It’s time to end the war on vaping

Retrieved on: 
Thursday, June 3, 2021
Tobacco, Electronic cigarettes, Cigarettes, Smoking, Smoking cessation, Health effects of tobacco, Electronic cigarette, Dosage forms, Tobacco control, Positions of medical organizations on electronic cigarettes, Usage of electronic cigarettes

Surgeon General, and as a lawyer representing injured smokers and state attorneys general in litigation against the tobacco industry.

Key Points: 
  • Surgeon General, and as a lawyer representing injured smokers and state attorneys general in litigation against the tobacco industry.
  • The THR community emphasizes the potential benefits of vaping for adult smokers who cannot or will not quit smoking otherwise.
  • The Canadian Vaping Association commends Douglas for trying to bridge the gap between tobacco control and vape advocates.
  • There are ways to prevent youth use that wont inflict harm on adult smokers, said Darryl Tempest, Executive Director of the CVA.

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Dosage forms, Injection, Routes of administration, Comorbidity, Subcutaneous

Non-significant reductions in SBP and DBP were observed during the follow-up period (0.34 and 0.59, respectively [P = 0.8374 and 0.5624, respectively]).

Key Points: 
  • Non-significant reductions in SBP and DBP were observed during the follow-up period (0.34 and 0.59, respectively [P = 0.8374 and 0.5624, respectively]).
  • Among patients with comorbid HTN, no increases were observed in mean SBP and DBP levels with AJOVY treatment.
  • This poster, Real-World Impact of AJOVY Use on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension, is included in the online program.
  • 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections.

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

Retrieved on: 
Thursday, June 3, 2021
Health sciences, Health care, Health, Dosage forms, Pharmacy, Hepatotoxins, Chemical engineering, Pharmaceutical industry, Tablet, Combined oral contraceptive pill, Adherence, Polypill

The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.

Key Points: 
  • The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.
  • In addition to the original 20 mg strength tablets, XPOVIO is now available in 40 mg, 50 mg, and 60 mg strength tablets.
  • XPOVIO tablets are available in seven different package sizes to help healthcare providers individualize the dosing and administration of XPOVIO based on patient needs.
  • The additional dosage strength tablets may also increase patient compliance by simplifying their treatment regimen and reducing the pill burden experienced by some patients.

Global Toothpaste Market (2020 to 2026) - Featuring 3M, Amway and Dabur India Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Retail, Health, Dental, Other Retail, Mouth, Oral hygiene, Dentifrices, Dosage forms, Teeth, Health sciences, Dentistry, Toothpaste, Marketplace

The global toothpaste market is anticipated to grow at a CAGR 6.1% during the forecast period.

Key Points: 
  • The global toothpaste market is anticipated to grow at a CAGR 6.1% during the forecast period.
  • The global toothpaste market is segmented based on type and distribution channels.
  • Further, the distribution channel segment of the global toothpaste market is bifurcated into offline channels and online channels.
  • The global toothpaste market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World.

Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement for SipNose Cribriform Targeted Device

Retrieved on: 
Tuesday, June 1, 2021
Biotechnology, Medical devices, Other Health, Health, Pharmaceutical, Health sciences, Clinical medicine, Dosage forms, Nasal administration, Yokneam, Cribriform, Glaucoma, Health, ST266, Noveome Biotherapeutics, Inc., SipNose Cribriform Targeted Device, SipNose Ltd., ST266, NOVEOME BIOTHERAPEUTICS, INC., SIPNOSE CRIBRIFORM TARGETED DEVICE, SIPNOSE LTD.

Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).

Key Points: 
  • Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).
  • Noveome and SipNose have established a great working relationship which has enabled a successful collaboration, said William J.
  • Noveome recently closed enrollment and completed the treatment phase of its Phase 1 safety study using the SipNose device to administer ST266 to Glaucoma Suspect patients.
  • Based in Israel, SipNose is a clinical stage nasal delivery company that has developed an innovative Cribriform Targeted Device for non-invasive delivery of pharmaceuticals.

NRI USA Medical Suppliers, TrueVision Technologies and Peach Medical Sourcing, Team-Up to Supply India Oxygen Concentrators

Retrieved on: 
Friday, May 28, 2021
Industrial gases, Oxygen, Medicine, Health sciences, Clinical medicine, Respiratory therapy, Dosage forms, Medical equipment, Oxygen concentrator, Oxygen therapy, Oxygen tank

Since late March 2021, India has been facing a new wave of a Covid-19 variant that has crippled the existing healthcare infrastructure.

Key Points: 
  • Since late March 2021, India has been facing a new wave of a Covid-19 variant that has crippled the existing healthcare infrastructure.
  • "Our team quickly sprung into action and worked with our distributors to purchase oxygen concentrators for NGOs, private donors, and individuals.
  • "To complement our US team's efforts, we have contracted with 3 Chinese manufacturers through our local subsidiary to provide India specification 220V oxygen concentrators," says Nitin Khosla, CEO of Peach Medical Sourcing.
  • We have 2 planes leaving weekly filled with all relief supplies including oxygen concentrators and accessories, oxygen tanks, masks, gowns and much more."

Premium Manufacturing Solutions Company Sending Oxygen to India

Retrieved on: 
Thursday, May 27, 2021
Oxygen, Industrial gases, Chemistry, Medicine, Physical sciences, Respiratory therapy, Dosage forms, Medical equipment, Oxygen concentrator, Oxygen therapy, Oxygen mask, Oxygen tank

SHANGHAI, May 27, 2021 /PRNewswire/ -- International sourcing company Source Access has extended their corporate responsibility to contribute to the growing oxygen concerns in India.

Key Points: 
  • SHANGHAI, May 27, 2021 /PRNewswire/ -- International sourcing company Source Access has extended their corporate responsibility to contribute to the growing oxygen concerns in India.
  • Source Access is working with hospitals in India to help get them Oxygen Concentrators.
  • Global systems regulate who can receive oxygen, and with it being a lifesaving treatment for the virus, many oxygen systems in hospitals across India require refills that they are not getting access to.
  • "We've dedicated our team to secure PPE products such as oxygen tanks to go out to India as priority shipments."

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Gastroenterology, Clinical medicine, Chloroarenes, Antiemetics, Prolactin releasers, Dosage forms, Gastroparesis, Metoclopramide, Forward-looking statement, Nasal spray

You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].

Key Points: 
  • You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].
  • The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • These forward-looking statements include statements regarding Evokes expectations on the social media marketing campaign.

Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study

Retrieved on: 
Tuesday, May 25, 2021
Psychoactive drugs, Dosage forms, Medical food, Medium-chain triglyceride, Triglycerides, MCT, Nicotine, Formulation

They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.

Key Points: 
  • They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.
  • Though new to NASDAQ, Lexaria Bioscience Corp. has been producing positive test results with their patented DehydraTECHTM bio-absorption technology since 2016.
  • But now, test results from May of 2021 showed a CBD delivery rate that was up to 2,708% stronger than medium chain triglyceride (MCT) oils which have become industry standard.
  • In November of 2020, Lexaria published a list of 2021 strategic initiatives that also targets hypertension treatment, nicotine delivery, and antiviral absorption.